Camille joined UNITY as Senior Vice President of Corporate Development in May 2018. Prior to UNITY, Camille was the Chief Business Officer at Eidos Therapeutics, where she led corporate development and financing activities. Prior to Eidos, Camille served as Vice President of Corporate Development at Relypsa, where she was responsible for building and leading corporate development, alliance management and strategic planning. She led the sale process of Relypsa to Galencia for $1.5B and supported the company's IPO and financing activities, which raised over $475M. She also led Relypsa's global partnering effort that resulted in a $165M licensing agreement with Vifor Fresenius Medical Renal Pharma and a co-detailing agreement with Sanofi. Additionally, Ms. Landis served on Relypsa's executive leadership team and led the company's annual strategic planning process. Ms. Landis also led Corporate Development efforts at Affymax and held multiple positions in finance, business development and commercial operations. Earlier in her career, Ms. Landis served as a life sciences strategy consultant with Frontline Consulting, acquired by Navigant, and as an investment banking analyst with Piper Jaffray’s healthcare investment banking practice, helping companies raise capital and advising on mergers and acquisitions.
Ms. Landis holds a M.B.A. from the Haas School of Business, University of California, Berkeley, and a B.A. in human biology from University of St. Thomas.